Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy

Cancer Research

Volumn 66, Issue 20, 2006, Pages 10073-10082

  Pastorino, Fabio ^a   Brignole, Chiara ^a   Di Paolo, Daniela ^a   Nico, Bice ^b   Pezzolo, Annalisa ^a   Marimpietri, Danilo ^a   Pagnan, Gabriella ^a   Piccardi, Federica ^c   Cilli, Michele ^c   Longhi, Renato ^d   Ribatti, Domenico ^b   Corti, Angelo ^e   Allen, Theresa M ^f   Ponzoni, Mirco ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d CNR   (Italy)

^e San Raf faele Institute   (Italy)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGD2 STABILIZED IMMUNOLIPOSOMAL DOXORUBICIN; DISIALOGANGLIOSIDE RECEPTOR GD2; DOXORUBICIN; GANGLIOSIDE GD2; IMMUNOLIPOSOME; LIPOSOME; MICROSOMAL AMINOPEPTIDASE; NGR LIPOSOMAL DOXORUBICIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOXORUBICIN; FEMALE; GANGLIOSIDES; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MICE, SCID; MYELIN PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; RECEPTORS, CELL SURFACE; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33750552967     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2117     Document Type: Article

References (51)

1. Folkman J. Transplacental carcinogenesis by stilbestrol. N Engl J Med 1971;285:404-5.
2. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185-8.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
4. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;3:1011-27.
5. Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002;296:2404-7.
6. Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000;60:722-7.
7. Marchio S, Lahdenranta J, Schlingemann RO, et al. Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell 2004;5:151-62.
8. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80.
9. Curnis F, Sacchi A, Borgna L, et al. Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000;18:1185-90.
10. Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999;5:1032-8.
11. Pastorino F, Brignole C, Marimpietri D, et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 2003;63:7400-9.
12. Siemann DW, Mercer E, Lepler S, et al. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002;99:1-6.
13. Siim BG, Lee AE, Shalal-Zwain S, et al. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2003;51:43-52.
14. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-92.
15. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750-63.
16. Schulz G, Cheresh DA, Varki NM, et al. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 1984;44:5914-20.
17. Raffaghello L, Pagnan G, Pastorino F, et al. In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma. Int J Cancer 2003;104:559-67.
18. Pagnan G, Stuart DD, Pastorino F, et al. Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects. J Natl Cancer Inst 2000;92:253-61.
19. Brignole C, Pastorino F, Marimpietri D, et al. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. J Natl Cancer Inst 2004;96:1171-80.
20. Pastorino F, Brignole C, Marimpietri D, et al. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 2003;63:86-92.
21. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-79.
22. Moss TJ, Reynolds CP, Sather HN, et al. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 1991;324:219-26.
23. Meitar D, Crawford SE, Rademaker AW, et al. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996;14:405-14.
24. Sugiura Y, Shimada H, Seeger RC, et al. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res 1998;58:2209-16.
25. Ribatti D, Alessandri G, Vacca A, et al. Human neuroblastoma cells produce extracellular matrix-degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo. Int J Cancer 1998;77:449-54.
26. Hansen CB, Kao GY, Moase EH, et al. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta 1995;1239:133-44.
27. Lode HN, Xiang R, Varki NM, et al. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 1997;89:1586-94.
28. Burbridge MF, Kraus-Berthier L, Naze M, et al. Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity. Int J Oncol 1999;15:1155-62.
29. Boehle AS, Dohrmann P, Leuschner I, et al. An improved orthotopic xenotransplant procedure for human lung cancer in SCID bg mice. Ann Thorac Surg 2000;69:1010-5.
30. Ponzoni M, Bocca P, Chiesa V, et al. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res 1995;55:853-61.
31. Ribatti D, Gualandris A, Bastaki M, et al. New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. J Vasc Res 1997;34:455-63.
32. Brignole C, Marimpietri D, Pastorino F, et al. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis J Natl Cancer Inst 2006;98:1142-57.
33. Richardson DS, Johnson SA. Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. Blood Rev 1997;11:201-23.
34. Raffaghello L, Marimpietri D, Pagnan G, et al. Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. Cancer Lett 2003;197:205-9.
35. Lopes de Menezes DE, Hudon N, McIntosh N, et al. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res 2000;6:2891-902.
36. Li M, Ye C, Feng C, et al. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clin Cancer Res 2002;8:3570-8.
37. Brouckaert P, Takahashi N, van Tiel ST, et al. Tumor necrosis factor-α augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics. Int J Cancer 2004;109:442-8.
38. Straubinger RM, Arnold RD, Zhou R, et al. Antivascular and antitumor activities of liposome-associated drugs. Anticancer Res 2004;24:397-404.
39. Di Matteo P, Curnis F, Longhi R, et al. Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. Mol Immunol 2006;43:1509-18.
40. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36.
41. Allen TM, Mumbengegwi DR, Charrois GJ. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-celi lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res 2005;11:3567-73.
42. Laginha KM, Verwoert S, Charrois GJ, et al. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 2005;11:6944-9.
43. Pastorino F, Stuart D, Ponzoni M, et al. Targeted delivery of antisense oligonucleotides in cancer. J Control Release 2001;74:69-75.
44. Pagnan G, Montaldo PG, Pastorino F, et al. GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int. J Cancer 1999;81:268-74.
45. Sapra P, Allen TM. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res 2004;10:2530-7.
46. Iden DL, Allen TM. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta 2001;1513:207-16.
47. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 2005;23:3235-42.
48. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
49. De Raima M, Venneri MA, Galli R, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005;8:211-26.
50. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005;23:939-52.
51. Schlingemann RO, Oosterwijk E, Wesseling P, et al. Aminopeptidase A is a constituent of activated pericytes in angiogenesis. J Pathol 1996;179:436-42.